Department of Medicine, Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 10003, USA.
J Rheumatol. 2011 Jul;38(7):1309-16. doi: 10.3899/jrheum.101091. Epub 2011 Apr 1.
To analyze quantitative data in patients with systemic lupus erythematosus (SLE), seen in usual care, from a patient Multidimensional Health Assessment Questionnaire (MDHAQ) with routine assessment of patient index data (RAPID3) scores and from a physician global estimate of noninflammatory symptoms; and to compare results to self-report Systemic Lupus Activity Questionnaire (SLAQ) scores and 4 SLE indices: SLE Disease Activity Index-2K (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Systemic Lupus Activity Measure (SLAM), and European Consensus Lupus Activity Measurement (ECLAM).
Fifty consecutive patients with SLE were studied in usual care of one rheumatologist. All patients completed an MDHAQ/RAPID3 in this setting. Each patient also completed a SLAQ. The rheumatologist scored SLEDAI-2K, BILAG, SLAM, ECLAM, and 2 physician global estimates, one for overall status and one for noninflammatory symptoms. Patients were classified into 2 groups: "few" or "many" noninflammatory symptoms. Scores and indices were compared using correlations, cross-tabulations and t tests.
The patients included 45 women and 5 men. MDHAQ/RAPID3 and SLAQ scores were significantly correlated. RAPID3 scores were significantly higher in patients with SLE index scores above median levels, and in 34 patients scored by the rheumatologist as having "few" noninflammatory symptoms. MDHAQ/RAPID3 and SLAQ were significantly higher in 16 patients scored as having many noninflammatory symptoms.
MDHAQ/RAPID3 and SLAQ subscale scores appear to reflect disease activity in patients with SLE, but not in patients with many noninflammatory symptoms. A physician scale for noninflammatory symptoms is useful to interpret MDHAQ/RAPID3, SLAQ, and SLE index scores.
分析系统性红斑狼疮（SLE）患者在常规护理中的定量数据，这些数据来自患者多维健康评估问卷（MDHAQ）与常规评估患者指数数据（RAPID3）评分，以及医生对非炎症症状的总体估计；并将结果与患者自我报告的系统性红斑狼疮活动问卷（SLAQ）评分和 4 个 SLE 指标进行比较：SLE 疾病活动指数-2K（SLEDAI-2K）、不列颠群岛狼疮评估组（BILAG）、系统性红斑狼疮活动量表（SLAM）和欧洲共识狼疮活动测量（ECLAM）。
对一位风湿病医生常规护理的 50 例连续 SLE 患者进行了研究。所有患者均在常规护理中完成了 MDHAQ/RAPID3。每位患者还完成了 SLAQ。风湿病医生对 SLEDAI-2K、BILAG、SLAM、ECLAM 和 2 项医生总体估计进行评分，一项是总体状况，另一项是无炎症症状。患者分为两组：“少数”或“多数”无炎症症状。使用相关性、交叉表和 t 检验比较评分和指标。
患者包括 45 名女性和 5 名男性。MDHAQ/RAPID3 和 SLAQ 评分显著相关。SLE 指数评分高于中位数水平的患者，以及 34 名被风湿病医生评为“少数”无炎症症状的患者的 RAPID3 评分显著较高。16 名被评为有多数无炎症症状的患者的 MDHAQ/RAPID3 和 SLAQ 显著较高。
MDHAQ/RAPID3 和 SLAQ 子量表评分似乎反映了 SLE 患者的疾病活动，但在多数无炎症症状的患者中则不然。用于非炎症症状的医生评分有助于解释 MDHAQ/RAPID3、SLAQ 和 SLE 指数评分。
